Effects of Renin–Angiotensin Inhibitors, Sodium–Glucose Cotransporter 2 Inhibitors, Mineralocorticoid Receptor Antagonists and Glucagon‐Like Peptide 1 Receptor Agonists on Kidney Outcomes in Patients With Type 1 Diabetes: A Systematic Review and Meta‐Analysis
Diabetes, Obesity and Metabolism · 2026-12 · 28 (12) · 11320-11327
DOI: 10.1111/dom.71337 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift Diabetes, Obesity and Metabolism, online erschienen am 13.09.2026. Verfasst von Frances Perry und 12 weiteren Autor:innen. Beteiligte Einrichtung: Internal Medicine, University of Manitoba College of Medicine, Winnipeg, Manitoba, Canada. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 1, Sodium-Glucose Transporter 2 Inhibitors, Glucagon-Like Peptide-1 Receptor Agonists, Diabetic Nephropathies. Die Arbeit nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Bayer.
Themen: Diabetes mellitus
Abstract (Originalsprache)
Aims
While the new kidney protective therapies have transformed chronic kidney disease (CKD) management in patients with Type 2 diabetes mellitus (T2DM), treatment options for CKD in Type 1 diabetes mellitus (T1DM) have remained unchanged for 30 years, limited to renin–angiotensin system inhibitors (RASis). Given similarities in pathophysiology between CKD in T1DM and T2DM, we conducted a systematic review and meta‐analysis evaluating sodium–glucose cotransporter‐2 inhibitors (SGLT‐2is), mineralocorticoid receptor antagonists (MRAs) and glucagon‐like peptide‐1 receptor agonists (GLP‐1RAs) on kidney function, albuminuria and safety outcomes. Materials and Methods We searched Medline, EMBASE, Cochrane CENTRAL, CINAHL, Global Health, LILACS and Scopus from inception until 11 April 2025, for randomised controlled trials (RCTs) evaluating RASi, MRAs, GLP‐1RAs and SGLT‐2is on change in urine albumin‐to‐creatinine ratio (UACR) and estimated glomerular filtration rate (eGFR) in adults (age ≥ 18) with T1DM.
Results
A total of 7151 unique records were identified and 41 RCTs were included in the meta‐analysis. No RCTs evaluating nsMRAs or MRAs met our inclusion criteria. Treatment with SGLT‐2i or RASi was associated with a 45% reduction in UACR versus placebo (GMR = 0.55; 95% CI: 0.32–0.94). No difference in the annual rate of eGFR change was observed across drug classes compared to placebo (mean difference 1.16 mL/min/1.73 m 2 /year; 95% CI: −0.38 to 2.70). Treatment was associated with a higher risk of hypoglycaemia (RR = 1.03; 95% CI: 1.01–1.05) and DKA (RR = 1.97; 95% CI: 1.33–2.93).
Conclusions
In patients with T1DM, the pooled analysis showed a reduction in UACR overall, but that this appeared to be driven predominantly by the SGLT‐2i studies, with limited and non‐significant evidence in the RAS inhibitor subgroup. Dedicated RCTs in the T1DM population could help establish the efficacy and safety of these different drug classes. Trial Registration PROSPERO registration: CRD420261352699.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Internal Medicine, University of Manitoba College of Medicine, Winnipeg, Manitoba, Canada.
- Chronic Disease Innovation Centre (CDIC), Winnipeg, Manitoba, Canada.
- Neil John Maclean Health Sciences Libraries, University of Manitoba, Winnipeg, Manitoba, Canada.
- US Medical Affairs, Bayer US LLC, Whippany, New Jersey, USA.
ORCID-Profile: Silvia J Leon, Ruth Getachew, Reid Whitlock
Förderung
- Bayer
Zitieren
APA
Perry, F., Leon, S. J., Polecina, K., Getachew, R., Askin, N., Ferguson, T., Whitlock, R., Zheng, Z., Aldworth, C., Katta, A., Earl, J., Beller Ferri, M., & Tangri, N. (2026). Effects of Renin–Angiotensin Inhibitors, Sodium–Glucose Cotransporter 2 Inhibitors, Mineralocorticoid Receptor Antagonists and Glucagon‐Like Peptide 1 Receptor Agonists on Kidney Outcomes in Patients With Type 1 Diabetes: A Systematic Review and Meta‐Analysis. Diabetes, Obesity and Metabolism, 28(12), 11320-11327. https://doi.org/10.1111/dom.71337
Vancouver
Perry F, Leon SJ, Polecina K, Getachew R, Askin N, Ferguson T, et al. Effects of Renin–Angiotensin Inhibitors, Sodium–Glucose Cotransporter 2 Inhibitors, Mineralocorticoid Receptor Antagonists and Glucagon‐Like Peptide 1 Receptor Agonists on Kidney Outcomes in Patients With Type 1 Diabetes: A Systematic Review and Meta‐Analysis. Diabetes, Obesity and Metabolism. 2026;28(12):11320-11327. doi:10.1111/dom.71337
BibTeX
@article{Perry2026,
author = {Perry, Frances and Leon, Silvia J and Polecina, Kate and Getachew, Ruth and Askin, Nicole and Ferguson, Thomas and Whitlock, Reid and Zheng, Zihe and Aldworth, Carolina and Katta, Arvind and Earl, Jacob and Beller Ferri, Mauricio and Tangri, Navdeep},
title = {Effects of Renin–Angiotensin Inhibitors, Sodium–Glucose Cotransporter 2 Inhibitors, Mineralocorticoid Receptor Antagonists and Glucagon‐Like Peptide 1 Receptor Agonists on Kidney Outcomes in Patients With Type 1 Diabetes: A Systematic Review and Meta‐Analysis},
journal = {Diabetes, Obesity and Metabolism},
year = {2026},
volume = {28},
number = {12},
pages = {11320--11327},
doi = {10.1111/dom.71337}
}
EUVIMED